GLOW Peptide Blend: Why BPC-157, TB-500 and GHK-Cu Are Studied Together

LynxLab · 24 October 2026 · 7 min read

What the wound-model research on BPC-157, thymosin beta-4 and GHK-Cu shows, whether the three have been tested as a combination, and where the evidence stops.

Photo: National Cancer Institute, Unsplash

The GLOW blend puts three peptides in one freeze-dried vial: BPC-157, TB-500 and GHK-Cu. Each has its own research history in skin and wound models, and the logic of the blend is that they act on different stages of repair. This post sets out what the published work on each component shows, and then asks the harder question: is there any research on the three together?

Wound repair has phases, and the three peptides map onto them

Textbooks divide healing into haemostasis, inflammation, proliferation and remodelling. Huang and colleagues (Drug Design, Development and Therapy, 2015) used exactly that four-phase framing to introduce their BPC-157 burn study, and it is the usual way skin researchers organise their questions.

Put simply, the proliferation phase needs new blood vessels and migrating cells. The remodelling phase needs collagen laid down and then reorganised. The three components of a glow peptide blend have each been studied against one or more of these steps, which is why they get grouped.

BPC-157: the pentadecapeptide in burn and incision models

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419. Almost all of its skin research comes from one group, led by Predrag Sikiric and Sven Seiwerth at the University of Zagreb.

Their 2021 review in Frontiers in Pharmacology lists the skin models: incisional and excisional wounds (1997), deep burns (2001), diabetic ulcers (2007) and alkali burns (2015). All are animal studies. The group's recurring observation is that the same regimen that heals gastric lesions also improves healing in tendon, ligament, muscle and skin.

The alkali burn work was done in China. Huang and colleagues applied BPC-157 to alkali burns in rats and ran parallel cell assays. In vitro, the peptide increased proliferation and migration of human umbilical vein endothelial cells and raised expression of c-Fos, c-Jun and Egr-1, genes tied to cell growth and angiogenesis.

TB-500: the actin-binding fragment of thymosin beta-4

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein present in almost every cell and released by platelets at a wound. TB-500 is a synthetic copy of its central actin-binding region, the seven residues LKKTETQ; the FDA's compounding list describes it as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500".

The foundational skin study is Malinda and colleagues in the Journal of Investigative Dermatology in 1999. In a rat full-thickness wound model, Tβ4 given topically or intraperitoneally increased re-epithelialisation by 42% over saline at day 4 and by as much as 61% at day 7, with more wound contraction, collagen deposition and angiogenesis. In a Boyden chamber, 10 picograms of Tβ4 stimulated keratinocyte migration two- to three-fold.

Philp and colleagues followed in 2003 with db/db diabetic mice and 26-month-old aged mice, both models of impaired healing. Tβ4 sped repair in both, and the synthetic LKKTETQ fragment promoted repair in the aged animals "comparable to that observed with the parent molecule". That paper is the reason a short fragment, rather than the whole protein, ended up in research catalogues as TB-500.

Tβ4 is the one component with human trial data. Goldstein's group summarised two phase 2 trials in venous stasis and pressure ulcers (Annals of the New York Academy of Sciences, 2012), reporting that in patients who did heal, healing was faster by almost a month. Those trials used the full protein, not the fragment, and the compound has not been licensed.

GHK-Cu: the copper tripeptide and collagen

GHK is glycyl-L-histidyl-L-lysine, a tripeptide that binds copper(II) and circulates in human plasma. Loren Pickart isolated it in 1973. In a 2015 review in BioMed Research International, Pickart reported plasma GHK at about 200 ng/mL at age 20, falling to 80 ng/mL by age 60.

The collagen finding is older and more specific. Maquart and colleagues (FEBS Letters, 1988) showed that GHK-Cu stimulated collagen synthesis in cultured fibroblasts, with stimulation beginning between 10^-12 and 10^-11 M and peaking at 10^-9 M, independent of any change in cell number. They noted that the GHK sequence occurs in the alpha-2 chain of type I collagen, and suggested the tripeptide is released by proteases at a wound site.

Of the three components, GHK-Cu has the longest clinical history, but mostly in cosmetic creams. A 2026 systematic review of 64 records concluded that the preclinical evidence is "deep" and "mechanistically coherent" while the human literature "remains thin and fragmented", built on small trials of facial creams.

Is there any research on the three together?

This is the honest gap. Searching PubMed for the three peptides as a combination returns nothing. There is no published study, in cells, animals or people, of BPC-157 plus TB-500 plus GHK-Cu.

There is one recent two-peptide study. Biçer and colleagues (Joint Diseases and Related Surgery, July 2026) transected the Achilles tendons of 32 rats and compared BPC-157, TB-500 and the two combined against controls over four weeks. Both single agents improved tendon histology; TB-500 alone also raised load to failure. Combined treatment "did not confer additional benefits compared to either agent alone".

That is tendon, not skin, and it is one exploratory study. But it is the only controlled test of two GLOW components together, and it did not find synergy. Anyone planning to buy glow for a laboratory project should treat the combination itself as the untested variable.

Why researchers buy a blend rather than three vials

If the combination is unproven, why does the format exist? The practical answer is that a blend is one vial to reconstitute, one lab report to read and one set of storage conditions. A laboratory testing fibroblast migration against a three-peptide cocktail wants a fixed ratio from a single source rather than three pipetting steps and three sources of error. That fixed ratio is what laboratories ordering GLOW UK stock are paying for.

LynxLab stocks GLOW for research use as a 70mg blend vial at £59.99, with every component tested to 99% purity and the lab report on the product page. The companion post on how a multi-peptide vial is made and tested explains how the certificate reports each peptide separately.

The regulatory position in plain terms

None of the three peptides is a licensed medicine anywhere. The World Anti-Doping Agency's 2026 Prohibited List names "Thymosin-ß4 and its derivatives e.g. TB-500" under S2, and the US Anti-Doping Agency states that BPC-157 falls under S0, non-approved substances.

In the United States, the FDA placed BPC-157, TB-500 and injectable GHK-Cu in category 2 of its bulk drug substances list, meaning compounding is not permitted because of possible immunogenicity and limited safety data. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted narrowly to recommend BPC-157 and TB-500 for the 503A list against the advice of agency scientists; the recommendation is non-binding and no rule has followed.

In the UK, a glow 70mg vial is a laboratory reagent. It is sold for research use only, and the batch lab reports are the evidence of what is in it.

Frequently asked questions

Does the GLOW blend have any clinical trial evidence?

No. The three-peptide combination has never been tested in a published study. Of the components, only thymosin beta-4 (the full protein, not the TB-500 fragment) has phase 2 trial data, in venous stasis and pressure ulcers.

Why are BPC-157, TB-500 and GHK-Cu grouped for skin research?

Each has animal or cell data on a different stage of repair: BPC-157 on angiogenesis and burn healing in rats, thymosin beta-4 on keratinocyte migration and re-epithelialisation, GHK-Cu on fibroblast collagen synthesis. The grouping is a hypothesis about complementary mechanisms, not a tested result.

Is GLOW peptide legal in the UK?

GLOW is not a licensed medicine and is sold in the UK for laboratory research only. Two of its components, BPC-157 and TB-500, are prohibited in sport under the WADA list, and all three sit in the FDA's category 2 for compounding in the United States. Buying glow peptide uk stock for research is lawful; using it on a person is not what it is sold for.

Has anyone tested BPC-157 and TB-500 together?

Yes, once, in rats. Biçer and colleagues (2026) compared each peptide and the pair in an Achilles tendon repair model and found the combination gave no extra benefit over either alone. No skin study of the pair, or of all three GLOW components, exists.

Sources

Research use only

GLOW from LynxLab

70mg vials from £59.99. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy GLOW